Pneumococcal disease caused by serotype 19A: Review of the literature and implications for future vaccine development

Rene Reinert, Michael R. Jacobs, Sheldon Kaplan

Research output: Contribution to journalReview article

107 Scopus citations

Abstract

Streptococcus pneumoniae serotype 19A is associated with all forms of pneumococcal disease and was the first reported pneumococcal serotype with high-level penicillin and multidrug resistance. While the seven-valent pneumococcal conjugate vaccine (PCV7), which contains serotype 19F, has reduced rates of disease among children and adults, the incidence of disease due to nonvaccine and increasingly drug-resistant serotypes - predominantly serotype 19A - has increased. This review summarizes the published literature to analyze the factors contributing to the emergence of serotype 19A, the diseases associated with this serotype, and the importance of including this serotype in novel pneumococcal conjugate vaccines. A recently approved 13-valent vaccine includes this serotype, and is likely to significantly reduce the burden of disease due to serotype 19A.

Original languageEnglish (US)
Pages (from-to)4249-4259
Number of pages11
JournalVaccine
Volume28
Issue number26
DOIs
StatePublished - Jun 11 2010

Keywords

  • Pneumococcal conjugate vaccines
  • Serotype 19A
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Pneumococcal disease caused by serotype 19A: Review of the literature and implications for future vaccine development'. Together they form a unique fingerprint.

Cite this